About Us

Who we are

Outset Medical is changing dialysis – one of the largest, most expensive, and stagnant areas of healthcare. Headquartered in San Jose, California, Outset operates across the United States and manufactures in North America. Our team is innovative, talented, and growing quickly. Learn about careers at Outset.

What we do

We are focused on creating change, driving widespread adoption of new technology, and delivering on the promise of an improved experience for patients and lower cost of care for healthcare providers.

Why we do it

We are fueled by the opportunity to give people their lives back.

When we succeed, patients will be able to fit dialysis into their life instead of fitting their life around dialysis. They will ultimately determine when, where, and how they dialyze.

Evolution of Outset

How did we get here? A brief timeline of company milestones.

2010

HD+ is officially funded
2013

First human treatments on Tablo^® in Mexico City
2014

FDA clearance for acute and chronic use, and we gain a CE Mark
2015

HD+ becomes Outset Medical
2016

2nd generation of Tablo is initiated; home clinical trial begins
2017

First use of Tablo in the acute setting at Cleveland Clinic
2018

Tablo launches commercially
2019

Home IDE completed; U.S. Dept. of HHS selects Tablo for disaster relief
2020

FDA clearance for home use; Outset goes public, listed on NASDAQ
2021

Tablo receives landmark TPNIES approval from Centers for Medicare & Medicaid Services; releases inaugural ESG report
2022

Outset ranks #33 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™ list
Present Day

New data shows Tablo increases patient and physician likelihood to adopt home hemodialysis

We’re honored to be recognized for our impactful and innovative solutions.

fast-company-best-workplaces-for-innovators-2023

Leadership

Board of Directors

Leslie Trigg

Chair & CEO

Read bio

Leslie Trigg joined Outset in November 2014 as Chief Executive Officer and was elected Chair in 2022. Leslie joined Outset from Warburg Pincus where she was an Executive in Residence. Previously, she was Executive Vice President at Lutonix, a cardiovascular medical device company acquired by CR Bard. Prior to Lutonix, Leslie served as Chief Business Officer of AccessClosure, a vascular closure company acquired by Cardinal Health. Before joining AccessClosure, Leslie served as Vice President, Marketing for FoxHollow Technologies, helping to architect the strategy and commercial infrastructure that led to a successful IPO and subsequent acquisition by ev3/Covidien. Leslie’s management experience also includes senior leadership positions at Cytyc Corporation and breast cancer diagnostics company Pro-Duct Health, Inc., which was acquired by Cytyc. She began her medical device career at Guidant Corporation. Leslie also serves on the board of directors of the Medical Device Manufacturers Association (MDMA), and the board of directors of Exact Sciences Corporation (NASDAQ: EXAS). Leslie received her undergraduate degree from Northwestern University and her MBA from The Haas School of Business, UC Berkeley.

D. Keith Grossman

Lead Independent Director
Compensation Committee Chair

Read bio

Keith has been a leader in the medical technology industry for more than 35 years. He served as Chairman of the Board of Nevro Corporation (NVRO) from 2019 through April 2025 when the company was acquired by Globus Medical, Inc, previously serving as Nevro’s President and CEO from 2019 through April 2023. Prior to Nevro, he was named President and CEO of Thoratec Corp. (THOR) for the second time in 2014. He led the company’s return to growth, a 2.5x increase in company value and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value prior to his arrival. From 2007 to 2011, he served as Managing Director for TPG Biotech, the $1.1 billion venture capital arm of the private equity firm Texas Pacific Group (TPG) where he co-led the medical device investment initiatives. Prior to TPG, he served as CEO, President and Director of Thoratec from 1996 to 2006, increasing the company’s market value more than 12x, and leading the company from no revenue to more than $200 million in annual revenues. Prior to Thoratec, he held a number of commercial and general management roles with companies including SulzerMedica and American Hospital Supply Corp. He currently serves as Vice Chairman of Alcon Inc. (ALC), and, in addition to his prior service on Nevro’s Board of Directors, he is a former member of the Board of Directors of ViewRay, Inc. (VRAY), Intuitive Surgical, Inc. (ISRG), Kyphon, Inc. (KYPH), Zeltiq (which was acquired by Allergan in 2017), and a number of private medical technology companies.

Karen Drexler

Director
Nominating & Corp. Gov. Committee Chair

Read bio

Karen is a healthcare industry veteran with a focus on chronic disease management, data analytics, and home based care. She has been an active board member for public and private medical device and diagnostics companies for over a decade. She currently sits on the boards of ResMed (NYSE:RSMD), EBR Systems (ASX:EBR), VIDA Diagnostics, and Huma.AI, and formerly served on the board of Tivic Health Systems (NASDAQ:TIVC). Most recently, she was CEO of Sandstone Diagnostics, a life science tools company focused on increased access to high-quality diagnostic testing. Previously, she founded and served as CEO at Amira Medical until its sale to Roche Diabetes Care. She started her career at LifeScan, where she managed a variety of functions and ultimately executed the sale of the company to Johnson & Johnson.

Patrick T. Hackett

Director

Read bio

Patrick is a Special Limited Partner of Warburg Pincus (NYSE:WPCA). He joined Warburg Pincus in 1990 and in his 29 years at Warburg Pincus, he has focused on investments in the technology and health care services fields. Prior to joining Warburg Pincus, he was the Vice President of Cove Capital Associates, a private merchant banking partnership, and prior to that a partner with private equity firm, Acadia Partners. He is a Director of Intelligent Medical Objects, a private healthcare software company. In addition, he serves on the Board of Directors at Stamford Health System, a nonprofit community hospital in Connecticut. He graduated from the University of Pennsylvania with a B.A. in chemistry, and holds a B.S. in economics from the Wharton School at the University of Pennsylvania.

Brent D. Lang

Director

Read bio

Brent served as Chairman and Chief Executive Officer of Vocera Communications, a global provider of clinical communication and workflow solutions, until its acquisition by Stryker in 2022. Including his role as Chairman and CEO, he spent more than 20 years in various leadership positions at Vocera, including President and Chief Operating Officer and Vice President of Marketing and Business Development. Earlier in his career, he held leadership roles at 3Com Corporation and worked as a strategy consultant for Monitor Company, Inc. Brent was Chairman of the board of Movella Holdings Inc., a company specializing in movement digitization, from November 2021 to April 2025, and also served as a member of the board of directors of Thriveworks, a private company that provides mental health services. Brent holds a B.S. from the University of Michigan and an M.B.A. from the Stanford University Graduate School of Business. He was also a gold medalist member of the 1988 U.S. Olympic swimming team.

Kevin O’Boyle

Director
Audit Committee Chair

Read bio

Kevin served on the board of directors of Nevro Corp., a global medical device company, from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc. He also served as Chairman of the board of directors of GenMark Diagnostics, Inc., a diagnostics company until its acquisition by Roche in May 2021. Additionally, Kevin also served on the boards of directors of Sientra, Inc., a medical aesthetics company, from May 2014 to June 2023, Wright Medical Group N.V. (acquired by Stryker), a global medical device company, from November 2015 to November 2020, Zeltiq Aesthetics, Inc. (acquired by Allergan), a medical aesthetics company, from July 2011 to April 2017, and Durata Therapeutics, Inc. (acquired by Actavis), a pharmaceutical company, from May 2012 to November 2014. He also currently serves on the board of directors of Carlsmed, a private company specializing in personalized spine surgery solutions. Previously, Kevin served as Senior Vice President and Chief Financial Officer of Advanced Biohealing Inc., a medical device company, from December 2010 until it was acquired in July 2011. Prior to that, he served as Chief Financial Officer of NuVasive, Inc., a medical device company, from January 2003 to December 2009. Earlier in his career, he served in various leadership positions during his six years with ChromaVision Medical Systems, Inc. Kevin holds a B.S. in Accounting from the Rochester Institute of Technology.

Andrea Saia

Director

Read bio

Andrea is an accomplished global business leader having focused her 40-year career building leading multinational brands in the consumer products and medical technology businesses with Novartis, Unilever, Revlon and Procter & Gamble. She currently serves on the board of Align Technology plc (NASDAQ: ALGN). She also served on the boards of Livanova plc and Coca Cola Enterprises. Previously, she was Global Head of Vision Care for Alcon and CEO/President of Cibavision, a Novartis division.

Learn more about opportunities at Outset.

Visit our careers page

About Us

Evolution of Outset

HD+ is officially funded

First human treatments on Tablo® in Mexico City

FDA clearance for acute and chronic use, and we gain a CE Mark

HD+ becomes Outset Medical

2nd generation of Tablo is initiated; home clinical trial begins

First use of Tablo in the acute setting at Cleveland Clinic

Tablo launches commercially

Home IDE completed; U.S. Dept. of HHS selects Tablo for disaster relief

FDA clearance for home use; Outset goes public, listed on NASDAQ

Tablo receives landmark TPNIES approval from Centers for Medicare & Medicaid Services; releases inaugural ESG report

Outset ranks #33 Fastest-Growing Company in North America on the Deloitte Technology Fast 500™ list

New data shows Tablo increases patient and physician likelihood to adopt home hemodialysis

We’re honored to be recognized for our impactful and innovative solutions.

Leadership

Chair and CEO

Chief Financial Officer

Chief Medical Officer

General Counsel

SVP, Operations and R&D

Head of Investor Relations

SVP, Sales

SVP, Customer Experience

SVP, Regulatory Affairs and Quality Assurance

VP, R&D and Supply Chain

VP, Controller

VP, People Operations and Culture

VP, Information Technology

Board of Directors

Learn more about opportunities at Outset.

First human treatments on Tablo^® in Mexico City